Skip to main content
main-content

Type 2 diabetes

medwireNews top story

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

Kidneys

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

medwireNews top story

SOLOIST-WHF: Sotagliflozin beneficial when started shortly after acute heart failure episode

Male orderly pushing male patient discharged from hospital in wheelchair

Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.

medwireNews top story

Rural inhabitants may miss out on newest diabetes medications

Remote landscape Victoria, Australia

Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.

medwireNews top story

FIDELIO-DKD: Finerenone offers new treatment option for diabetic CKD

Kidneys

The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.

medwireNews top story

VERTIS CV secondary analyses indicate ertugliflozin protection against HF

Heart and white pills

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

EASD 2020

EMPEROR-Reduced: Time for a change in the HF guidelines?

Miles Fisher

Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).

EASD 2020

DAPA-CKD trial: Renal benefits of SGLT2 inhibition in people with and without diabetes

Hiddo Heerspink

DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).

EASD 2020

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes

Milton Packer

Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).

EASD 2020 news

Intermittent very-low-calorie diet could be easier to stomach for people with diabetes

Man checking body fat (symbolic image with model)

The pilot MIDDAS study suggests that a 2-day per week very-low-calorie diet could be a viable alternative to a continuous diet for people with type 2 diabetes who struggle with this approach.

EASD 2020

COVID-19 and diabetes: The current evidence

Juliana Chan

Juliana Chan outlines current knowledge about the relationship between diabetes and COVID-19, discussing risk factors for poor outcomes in people with both conditions and the need for collaborative efforts to improve patient care (7:09).

EASD 2020 News

LIBERATES trial results: Hypoglycemia reduction with post-ACS flash monitoring in type 2 diabetes

Woman with flash glucose monitor (symbolic image with model)

The results of the phase 2 LIBERATES trial suggest that flash glucose monitoring could reduce the time people with type 2 diabetes spend in hypoglycemia in the period following an acute coronary syndrome.

medwireNews top story

SGLT2 inhibition ‘could overcome diuretic resistance’

Man handing container with urine sample to a doctor

A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.

medwireNews top story

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

Flatline alert_heart monitor

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

medwireNews top story

EMPEROR-Reduced boosts case for SGLT2 inhibition in HF irrespective of diabetes

Pills and water (symbolic image with model)

The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.

medwireNews top story

DAPA-CKD shows dapagliflozin benefits regardless of diabetes

Kidneys

The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.

medwireNews top story

‘Nearly identical’ metabolic benefits with surgery vs diet in people with type 2 diabetes

Bariatric surgery

Among people with obesity and type 2 diabetes, substantial weight loss is associated with similar metabolic benefits irrespective of whether it is achieved through gastric bypass surgery or diet, suggests research published in The New England Journal of Medicine.

medwireNews top story

Type 1, type 2 diabetes linked to elevated COVID-19 mortality risk

Doctor checking on Covid-19 infected patient connected to a ventilator

Both type 1 and type 2 diabetes are independently associated with an increased risk for death among hospitalized patients with COVID-19, and a number of factors including poor glycemic control and BMI may predict mortality risk, suggest findings from two studies published in The Lancet Diabetes & Endocrinology.

medwireNews top story

Ethnic-specific diabetes screening BMI cutoffs proposed

African American male patient having weight checked by doctor

Researchers studying the MESA cohort have proposed BMI cutoffs at which people from ethnic minorities should be screened for type 2 diabetes, all of which are lower than their proposed cutoff for White people.

medwireNews top story

Severe hypoglycemia ‘marker rather than cause’ for longer-term type 2 diabetes mortality risk

emergency_department

Severe hypoglycemia in people with type 2 diabetes is associated with later mortality from a wide range of causes, including those for which there is no obvious underlying mechanism, say researchers.

medwireNews top story

Nonvascular comorbidities highlighted in type 2 diabetes

Doctor patient consultation

A large study of data from people with type 2 diabetes in general practice reveals that non-cardiovascular comorbidities such as osteoarthritis and depression are common, and significantly more so than in people without diabetes.

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials

Phase 3 trials of tirzepatide in type 2 diabetes and obesity

Tirzepatide (formerly known as LY3298176) is a novel glucose-lowering medication that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.

10-14-2020 | Type 2 diabetes | Editorial | Article

Tirzepatide: A new challenger for type 2 diabetes management?

What does the future hold for the novel agent tirzepatide, a GIP/GLP-1 co-agonist? John Wilding examines what we know so far.

07-29-2020 | Type 2 diabetes | Podcast | Article

The DiRECT approach to weight loss: Efficacious and pragmatic

DiRECT trial dietitian Alison Barnes discusses the challenges and triumphs of using a very-low-calorie, total-meal-replacement diet to help people with type 2 diabetes achieve weight loss and maintenance (25:34).

Diagnosis and management of prediabetes: a consensus of GCC countries

Guidance based on outcomes of an advisory board of diabetes experts, for healthcare professionals addressing the diagnosis and treatment of prediabetes.

This interactive roadmap is intended for healthcare professionals practicing in Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman. 

Funding for this roadmap was provided by Merck Serono Middle East FZ-LLC

Access the interactive roadmap

Downloadable slides

10-31-2018 | Slideset | Collection

FreeStyle Libre collection

These slide sets summarize the results of clinical studies and randomized controlled trials investigating the use of flash glucose-sensing technology in patients with diabetes.

Funded by an educational grant from Abbott Diabetes Care

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

Image Credits